Onclast Tablets (Alendronate sodium) by Life Pharmaceutical Company
Drug Category: Phenylacetic Acid
Indication: Alendronate (Na) is primarily indicated in conditions like Osteoporosis in men, Osteoporosis prophylaxis, Pagets disease, Prevention and treatment of corticosteroid-induced osteoporosis, Treatment of osteoporosis in post menopausal women, and can also be given in adjunctive therapy as an alternative drug of choice in Hypercalcaemia associated with malignancy, Non-tumour induced hypercalcemia, Osteolytic tumoral bone disease.
Each Tablet contains:
- Alendronate sodium…………………………………………..10mg
- Alendronate: The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.